[Skip to Content]
[Skip to Content Landing]
Views 439
Citations 0
Comment & Response
December 22/29, 2015

Competition and Biosimilar Products—Reply

Author Affiliations
  • 1Harvard University, Cambridge, Massachusetts
  • 2Precision Health Economics, Los Angeles, California

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;314(24):2692. doi:10.1001/jama.2015.15058

In Reply Drs Frankel and McKay first note that the FDA is able to ensure biosimilar and reference biologic quality through prerelease specifications. But these specifications cover only a subset of all measurable quality attributes. If FDA testing were adequate to predict all emergent quality-related safety issues with biologics, then there never would have been cases of pure red blood cell aplasia associated with Eprex1 or HX575, which are biosimilar versions of epoetin-α, nor would have there have been deaths due to contaminated heparin in the United States in 2008.2

First Page Preview View Large
First page PDF preview
First page PDF preview